Edwin M. Posadas, MD, FACP, and E. David Crawford, MD, presented “Need to Know: Experience with Lutetium (Pluvicto) for Prostate Cancer Theranostics” for the Grand Rounds in Urology audience in March 2023.
How to cite: Posadas, Edwin M. Crawford, E. David. “Need to Know: Experience with Lutetium (Pluvicto) for Prostate Cancer Theranostics” March 2023. Accessed Nov 2024. https://grandroundsinurology.com/need-to-know-experience-with-lutetium-pluvicto-for-pca-theranostics/
Need to Know: Experience with Lutetium (Pluvicto) for Prostate Cancer Theranostics – Summary
E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology and Professor of Urology at the University of California, San Diego interviews Edwin M. Posadas, MD, FACP, Director of the Experimental Therapeutics Program and the Medical Director of the Center for Uro-Oncology Research Excellence (CURE) / Urologic Oncology Disease Research Group at Cedars-Sinai Medical Center on his clinical experience with lutetium Lu 177 vipivotide tetraxetan (PLUVICTO®). Dr. Crawford comments on the significance of both molecular-targeted imaging with PSMA and theranostics in treating prostate cancer. He then highlights the success of lutetium and asks Dr. Posadas how this treatment has impacted his practice. Dr. Posadas discusses several exceptional patient outcomes, including examples of patients who had previously undergone multiple rounds of chemotherapy or who had a poor future prognosis, noting these patients experienced remarkable disease control with few adverse events. Dr. Crawford then raises supply chain issues with lutetium and the difficulty of effectively treating patients with a popular drug in low supply. Dr. Posadas remarks that the result of current supply rationing means he cannot guarantee new lutetium treatment starts, underscoring the gravity of treatment delays for patients with advanced prostate cancer. Dr. Crawford recalls similar delays in accessing fluciclovine in years past. Dr. Posadas adds how distressing it is to see a revolutionary therapy that offers a life-saving benefit be delayed and offers hope that future government intervention could assist in stabilizing the supply chain.
For another recent discussion on the shortage of lutetium and its impact on PCa theranostics, click here.
E. David Crawford, MD
University of California San Diego
La Jolla, California
ABOUT THE AUTHOR
Edwin M. Posadas, MD, FACP, is Director of the Experimental Therapeutics Program and the Medical Director of the Center for Uro-Oncology Research Excellence (CURE) / Urologic Oncology Disease Research Group at Cedars-Sinai Medical Center. He is also an associate professor at Cedars-Sinai and a full professor at the University of California, Los Angeles. Dr. Posadas received his medical degree from Johns Hopkins and completed his residency at the University of Michigan before finishing a fellowship at the National Cancer Institute in Bethesda, Maryland.
Dr. Posadas’s clinical and research interests include the treatment of advanced prostate cancer and the biology of cancer metastasis. He is studying the mechanisms through which cancer cells in localized tumors spread to other parts of the body. Hais current research interests focus on the most aggressive subtypes of prostate cancer that spread to organs such as the liver and lungs. Dr. Posadas’s laboratory has been studying the role of circulating tumor cells (CTCs) and immune cells (ICs) as biomarkers in prostate and other cancers using novel nanotechnology platforms. Clinically, he specializes in the use of medical therapies for prostate, kidney, bladder, and testis cancer with an emphasis on integrated, trans-disciplinary care.
